Metabolic Characteristics of Plasma OxPLs in STEMI Patients.

Metabolic Characteristics of Plasma OxPLs in STEMI Patients and Its Value Analysis in Predicting MACEs Risk After PCI Surgery.

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07382700

Enrollment

240

Registered

2026-02-03

Start date

2025-01-01

Completion date

2027-12-31

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI - ST-segment Elevation Myocardial Infarction

Brief summary

The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in STEMI patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Based on the OxPLs fingerprint of STEMI patients, a machine learning classifier is used to establish an artificial intelligence assisted post PCI MACE risk prediction system, achieving the transformation of basic research into clinical application.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2021)") * Agree to perform direct PCI * The onset time is less than 12 hours and successfully undergoing emergency PCI treatment * After admission, all STEMI patients are routinely treated with antiplatelet aggregation, anticoagulation, lipid-lowering, and anti myocardial remodeling drugs.

Exclusion criteria

* Previous history of myocardial infarction * Accompanied by other cardiovascular diseases, such as severe heart valve disease, severe heart failure, congenital heart disease, cardiomyopathy, etc * Merge with severe infection * Merge with severe anemia * Merge with severe liver and kidney dysfunction * Combined with malignant tumors * Accompanied by a history of autoimmune or hematological diseases * Recent history of severe trauma or surgery * Patients with incomplete clinical data * The patient does not agree to undergo data collection

Design outcomes

Primary

Measure	Time frame
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0	12 months

Countries

China

Outcome results